

AMENDMENTS TO THE SPECIFICATION

Please replace the paper copy of the Sequence Listing with the Substitute paper copy of the Sequence Listing concurrently submitted.

Please delete the paragraph bridging page 15, line 26, to page 16, line 14, and replace it with the following paragraph:

Figure 3 is a graphical representation showing the anti-LHRH antibody titers obtained using each of the peptides and lipopeptides shown in Figure 1, wherein the polypeptide moieties have the amino acid sequences set forth in SEQ ID NO: 5 or SEQ ID NO: 7. A negative control lipopeptide designated Pam₃Cys-Ser-Lys₄ (**SEQ ID NO: 114**) consisted of the lipid of Formula (I) conjugated to the N-terminus of a peptide having the amino acid sequence Ser-Lys-Lys-Lys-Lys (SEQ ID NO: 17). All peptides and lipopeptides were administered sub-cutaneously (s.c.) in saline for both primary inoculation (open circles) and secondary inoculations (closed circles). The two non-lipidated peptides [Th]-Lys-[B] and [Th]-[B] were administered in complete Freund's adjuvant (CFA) for the primary inoculations, and in incomplete Freund's adjuvant (IFA) for the secondary inoculations. For administration of the peptide [Th]-[B] in combination with the lipopeptide Pam₃Cys-S-Lys₄ (**SEQ ID NO: 114**), peptide was dissolved in saline and mixed with the lipopeptide in 1:1 or 1:5 molar ratio as indicated. The dose of peptide and lipopeptide immunogens administered was 20 nmole. In all cases, control groups of animals received saline emulsified in CFA for priming and saline emulsified in IFA for the secondary inoculation.

Please delete the paragraph on page 17, lines 14-21, and replace it with the following paragraph:

Figure 6 is a graphical representation showing anti-LHRH antibody responses elicited by lipidated [Th]-Lys(Pam₂Cys)-[B] in which [Th] consists of CD4⁺ T cell epitope from the light chain of influenza haemagglutinin (SEQ ID NO: 1) and [B] is LHRH 1-10 (SEQ ID NO: 2) or LHRH 6-10 (i.e. the C-terminal 5 residues of LHRH; SEQ ID NO: 4), with or without a serine spacer (Ser-Ser) positioned between the lipid and peptide moieties. Lipopeptide [Th]-Lys(Pam₂Cys)-GlyLeuArgProGly (**SEQ ID NO: 115**) is structurally similar to [Th]-Lys(Pam₂Cys)-[B], however this lipopeptide comprises SEQ ID NO: 4 in place of SEQ ID NO: 2.